Published in:
Open Access 01-12-2015 | Letter
Continuous renal replacement therapy in critically ill patients does not affect urinary neutrophil gelatinase-associated lipocalin levels
Published in: Critical Care | Issue 1/2015
Login to get accessExcerpt
In the present study, we assessed urinary neutrophil gelatinase-associated lipocalin (uNGAL) during 24-hour continuous renal replacement therapy (CRRT) in critically ill patients. The study was performed in accordance with the Declaration of Helsinki and was approved by the Scientific Council and the Ethics Committee of Evangelismos Hospital in Athens, Greece. Informed consent was provided by family members of the patients included in the study. Eighteen critically ill patients (13 men and five women with a mean age of 69 ± 14 years) in an interdisciplinary intensive care unit underwent continuous veno-venous hemodiafiltration (CVVHD). Three had oliguria (urine output of less than 200 mL per 12 hours). Patient characteristics at enrollment are shown in Table 1.
Table 1
Patient characteristics (n = 18)
|
Patient characteristic
|
Number (percentage) of patients unless noted otherwise
|
|---|---|
|
APACHE II scorea
|
19.4 ± 7.5
|
|
SOFA scorea
|
9.2 ± 2.9
|
|
SAPSa
|
69.5 ± 14.2
|
|
Reason for admission
|
|
|
Trauma
|
1 (5.5%)
|
|
Post-operative
|
11 (61%)
|
|
Circulatory
|
4 (22%)
|
|
Respiratory
|
2 (11%)
|
|
SIRS
|
5 (28%)
|
|
Sepsis
|
4 (22%)
|
|
Septic shock
|
7 (39%)
|
|
RIFLE
|
|
|
No
|
2 (11%)
|
|
Risk
|
5 (28%)
|
|
Injury
|
10 (55.5%)
|
|
Failure
|
1 (5.5%)
|
|
Diabetes
|
6 (33%)
|
|
Vasopressors
|
11 (61%)
|